Korean Researchers Identify Gene Fusion Linked to Lung Cancer

By Bio-IT World Staff  

December 23, 2011 | Researchers in South Korea have identified a previously unknown gene fusion event that could explain a significant proportion of lung cancer cases in never-smokers, and might serve as a target for new therapies. The results were published online today in Genome Research.   

Using a combination of genome sequencing and RNA sequencing, the team characterized a previously unknown gene fusion event in a case of lung adenocarcinoma striking a 33-year-old Korean male with no history of smoking or cancer within his family. Seoul-based scientists from Macrogen Inc., Genomic Medicine Institute-Seoul National University, Seoul St. Mary’s Hospital, Seoul National University Hospital, and Psoma Therapeutics Inc. made up the research team.  

“We showed that genome sequencing technology could reveal a previously hidden cause of human cancer, which can be used as a therapeutic target for personal cancer therapy”, said Dr. Jeong-Sun Seo, director of the Genomic Medicine Institute-Seoul National University, chairman of Macrogen Inc., and senior author of the study said in a press release.   

The group sequenced and compared the genome of the patient’s cancer and normal tissue (blood), but they found no mutations in known-cancer related genes, such as EGFR , KRAS and EML4-ALK mutations, that were likely to explain this case.  Delving deeper, they also sequenced RNA isolated from the cancer cells, which when analyzed, can reveal gene rearrangement events that are difficult to detect by genome sequencing and may be driving the cancer.  

From the RNA sequencing analysis they built a list of candidate gene fusions, narrowing it down to a single gene fusion that could be a cancer-causing event.  A genomic inversion event occurred on chromosome 10 in the cancer, fusing the KIF5B and RET genes.  This fusion was particularly interesting because RET has been previously implicated in other gene fusion events known to drive thyroid cancers, and although it is normally expressed at low levels in the lung, chimeric RET in this patient is highly expressed.  Furthermore, KIF5B contains a protein domain that is necessary for activation of the fusion gene.  

They then confirmed that the KIF5B-RET fusion occurs in other lung cancer cases, finding two instances in twenty additional cases of lung cancer, indicating that this fusion event is not rare. The authors suggest that the KIF5B-RET fusion occurs in about 6% of all lung adenocarcinoma cases.  The authors note that although further epidemiological studies are needed to accurately define the frequency of KIF5B-RET in lung cancers, they expect that the fusion gene may be a promising molecular target for treatment.